Fusion Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Fusion Pharmaceuticals's estimated annual revenue is currently $14.6M per year.
- Fusion Pharmaceuticals's estimated revenue per employee is $127,807
- Fusion Pharmaceuticals's total funding is $170.9M.
- Fusion Pharmaceuticals's current valuation is $284.2M. (January 2022)
Employee Data
- Fusion Pharmaceuticals has 114 Employees.
- Fusion Pharmaceuticals grew their employee count by 4% last year.
Fusion Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | SVP, Business Development | Reveal Email/Phone |
3 | VP Quality | Reveal Email/Phone |
4 | VP, Corporate Controller | Reveal Email/Phone |
5 | VP Human Resources | Reveal Email/Phone |
6 | SVP, Research | Reveal Email/Phone |
7 | Associate Director Chemistry | Reveal Email/Phone |
8 | Senior Director, Preclinical Development | Reveal Email/Phone |
9 | Director, Intellectual Property Attorney | Reveal Email/Phone |
10 | Sr. Director External Manufacturing | Reveal Email/Phone |
Fusion Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.7M | 9 | -72% | $39.4M | N/A |
#2 | $0.9M | 11 | -83% | $23.8M | N/A |
#3 | $87.6M | 565 | 6% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $7.8M | 50 | -68% | N/A | N/A |
#6 | $13.5M | 87 | 30% | N/A | N/A |
#7 | $17.8M | 115 | -6% | N/A | N/A |
#8 | $0.9M | 11 | -39% | N/A | N/A |
#9 | $13.6M | 88 | -20% | $86M | N/A |
#10 | $20M | 129 | -12% | N/A | N/A |
What Is Fusion Pharmaceuticals?
Fusion Pharmaceuticals (www.fusionpharma.com) is a new pharmaceutical company located in Hamilton, Ontario, Canada, that is focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01, Fusion is building a pipeline of products through a protein discovery platform, that allows for the rapid screening of new targeting molecules to promote biomarker localization of alpha emitting medical isotopes. Fusion's technology development team also has proprietary methods for introducing alpha emitters into targeting molecules.
keywords:N/A$170.9M
Total Funding
114
Number of Employees
$14.6M
Revenue (est)
4%
Employee Growth %
$284.2M
Valuation
N/A
Accelerator
Fusion Pharmaceuticals News
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN Get Rating) CEO John Valliant sold 4,511 shares of the business's stock in a transaction that...
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer.
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
FPI-1434 Phase 1 multi-dose data now expected in 2H 2022 FPI-1966 Phase 1 study initiated; first patient expected to be dosed in Q1 2022 FPI-2059 investigational new drug application (IND) on track for first half 2022 HAMILTON, ON and BOSTON, Nov. 9, 2021 /PRNewswire/ -- Fusion Pharmaceutical ...
HAMILTON, Ontario and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the compensation committee of the Company's Board of ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $35M | 118 | 9% | N/A |
#2 | $31.5M | 119 | -2% | N/A |
#3 | $25M | 119 | 3% | N/A |
#4 | $34.5M | 119 | 6% | N/A |
#5 | $32.7M | 121 | 5% | N/A |